Ultragenyx Pharmaceutical... (RARE)
| Bid | 30.7 |
| Market Cap | 3.07B |
| Revenue (ttm) | 610.16M |
| Net Income (ttm) | -532.93M |
| EPS (ttm) | -5.43 |
| PE Ratio (ttm) | -5.86 |
| Forward PE | -8.67 |
| Analyst | Buy |
| Ask | 32.85 |
| Volume | 1,308,854 |
| Avg. Volume (20D) | 1,965,722 |
| Open | 31.61 |
| Previous Close | 31.28 |
| Day's Range | 31.28 - 32.26 |
| 52-Week Range | 25.81 - 60.37 |
| Beta | 0.24 |
About RARE
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for RARE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · fool.com
Ultragenyx (RARE) Q2 Revenue Up 13%Ultragenyx (RARE) Q2 Revenue Up 13%
1 month ago · seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call TranscriptUltragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief M...
1 month ago · seekingalpha.com
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 CatalystUltragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal da...
1 month ago · businesswire.com
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $RARE--RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm.
